InvestorsHub Logo
Followers 26
Posts 6461
Boards Moderated 4
Alias Born 03/20/2017

Re: None

Sunday, 04/29/2018 2:24:28 PM

Sunday, April 29, 2018 2:24:28 PM

Post# of 4847
Canntab Therapeutics (CSE: PILL) Files 11 Patent Applications Related to Pharmaceutical #Cannabis.

Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
* Sustained Release Cannabinoid Formulations;
* Immediate Release Cannabidiol Formulations;
* Modified-Release Multi-Layer Cannabinoid Formulations;
* Flash-Melt Cannabinoid Formulations; and
* Bi-layer Cannabinoid Tablets.
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that can be used to treat a number of ailments, such as
* sleep disorders;
* post-traumatic stress disorder (PTSD);
* social anxiety;
* addiction;
* arthritis;
* general pain; and
* the pain management and appetite loss associated with cancer treatments.

See QBL-board and website; https://www.queenslandbauxite.com/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.